Objective: Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking.
Methods: We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone.
Results: Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases.
Conclusion: Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DBP.0000000000000970 | DOI Listing |
Publication Analysis
Top Keywords
generalized anxiety
8
anxiety disorder
8
anxiety
5
buspirone treatment
4
treatment generalized
4
disorder syndrome
4
syndrome cases
4
cases objective
4
objective reports
4
reports pharmacologic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!